Mirwais Wardak

🚀Excited to co-chair a session with @Novartis and @Certara at #ACoP2025 in Aurora, CO! 🎯Advances in Mathematical & Computational Modeling for Radiopharmaceutical Therapies 🗓 Oct 21 | ⏰ 9–10 AM MDT | 📍 Red Rock 8/9 Hear from top experts in academia & industry—don’t miss it!

Someone suggested I make a table summarizing the video. Here it is!

Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.10…

Read it in the #RedJournal: Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report from the National Clinical Trials Network. @NRGOnc tinyurl.com/rjkovalchuk

In 2023, Stanford professor Matt Abrahams gave a masterclass on how to think fast & speak smartly on the spot. He explained: • Why anxiety destroys clarity • How structure beats intelligence • Secret to spontaneous charisma 12 lessons to master communication in real time:

Thank you so much to the @NRGonc Podcast for hosting me on this episode focused on how the @AmerMedicalAssn can collaborate with organizations like @ACRORadOnc, @ASCO, the @RadiologyACR and @ASTRO_org to ensure equitable clinical trial access for patients. Thanks so much @StephenChunMD and @lauren_henke for being excellent podcast hosts and for featuring this important topic! 🙏 #SDoH #clinicaltrials #ruralcancercare #healthdisparities #communityoncology #RadOnc #radvocacy #representationmatters

𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗖𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆 𝗨𝗦! Discover how #AI boosts model-informed drug development with #QSP, #PBPK, #MBMA, and #RWE. Register: certainty.certara.com/us/agenda/mode…

The newest @GreenstoneBio Webinar: Human Pluripotent Stem Cells, Organoids, and Drug Discovery featuring Dr. Shuibing Chen, Director of the Center of Genomic Health at Weill Cornell Medicine, is now available to watch online! youtube.com/watch?v=Kkee6t…

Proton therapy usually requires a facility the size of a football field- but @BLoo_LT_SABR and the team are shrinking the map. Full story on this breakthrough: dotmed.com/news/story/660… #HealthTech #ProtonTherapy #CancerResearch #Innovation

@SprakerMDPhD Link! nejm.org/doi/full/10.10… Great, balanced piece by our chair @BobTimmermanMD.

Advancing theranostics in #AlzheimerDisease: FDA approval of beta-amyloid PET drugs for selection of patients for beta-amyloid-directed therapies and other labeling updates. ow.ly/OBLz50YmVzv #NuclearMedicine #RPTherapy

Watch more Walk with Me videos: stanmed.stanford.edu/we-are-stanfor…

NEW President's Corner Member Spotlight - Freddy Escorcia, MD, PhD In the latest episode, ASTRO President Neha Vapiwala, MD, FASTRO, speaks with Freddy Escorcia, MD, PhD, executive director at RayzeBio Inc. and a special volunteer at the National Cancer Institute. @NehaVapiwala @freddyeescorcia Watch the video: ow.ly/sAht50YhKav

Mapping the Kidney at Single-Cell Resolution 🤖 #HelmholtzMunich and #Novartis Biomedical Research are launching a four-year collaboration to advance #KidneyDisease research. 👉 t1p.de/yf554 🔬 The partnership will develop an integrated, cross-species “kidney disease atlas” at single-cell resolution. By combining large-scale perturbation data with artificial intelligence, the collaboration aims to uncover new insights into kidney disease mechanisms and create enhanced preclinical disease models to accelerate therapeutic development. 💡 This initiative builds on Helmholtz Munich’s expertise in #AI-driven modeling, virtual cell simulations, and large-scale perturbation analysis. 🤝 @Novartis contributes extensive know-how in the generation and characterization of reproducible kidney organoid models – lab-grown tissue models that replicate key features of human kidneys and allow researchers to test potential therapies in physiologically relevant systems. @fabian_theis @CompHealthMuc @helmholtz_ai #CellAtlas #PerturbationModels #VirtualCell #Organoids

20 years of Yamanaka stem cell factor research culminates in 2 conditional approvals for heart disease and Parkinson's disease in Japan sciencedirect.com/science/articl… by Shinya Yamanaka @CellStemCell science.org/content/articl… @ScienceMagazine

Can an AI model be a generalist to work and perform well for all types of medical images? Just published, our MedVersa paper @NEJM_AI Led by @pranavrajpurkar Free access ai.nejm.org/stoken/default…

QSP is proven. Scaling it is the challenge. See how teams use Certara IQ™ to scale QSP and answer high-value development questions earlier and with greater confidence. Register now: ow.ly/Spe450Yoeb3 #CertaraIQ #QSP #ModelingAndSimulation

What REALLY makes a good oncologist? in @JCO_ASCO After 10 years and 203 JCO essays, one thing became clear: expertise alone isn’t enough. Patient-centered care. Clear, authentic communication. Emotional intelligence. And the harder work Showing up again and again. Openness to uncertainty. Carrying the burden of cancer care. Continuous growth. Clinical competence is expected Human connection makes the difference. Science treats disease. Presence treats fear. ascopubs.org/doi/pdf/10.120… @OncoAlert

Radiation oncology is changing fast. But radiation can still injure normal tissue. An excellent review in @NEJM explains how modern RadOnc is reducing that risk: -Precision planning -Adaptive radiotherapy -Biologic personalization -AI-assisted treatment design the goal is simple: maximize tumor control while protecting normal tissue nejm.org/doi/full/10.10… @OncoAlert

@garykbrixi @pdhsu @MichaelPoli6 @AlisonFanton @samuelhking @GoodfireAI @AnsaBio @NVIDIAHealth @genophoria @davey_burke Since last February, Evo 2 has seen 200+ citations, 88K+ downloads, and 8M+ API requests. Groups at Yale, Johns Hopkins, NCState & UW have applied Evo 2 to problems from Alzheimer's risk prediction to 3D genome structure

First released one year ago, Evo 2 predicts variant effects & generates functional DNA across all domains of life, from bacteria to humans, from a single set of weights, with no fine-tuning required.